This article provides a comprehensive overview of the field of biosynthetic gene cluster (BGC) identification, a foundational technology in modern drug discovery. It defines BGCs as physically clustered genes that encode the pathways for secondary metabolites, which are a primary source of therapeutics. The review details the paradigm shift from traditional, activity-based screening to targeted genome mining, a computational strategy that has revealed immense, previously hidden biosynthetic potential within microbial genomes. Key methodologies are explored, including the use of bioinformatics tools like antiSMASH for BGC detection, BiG-SCAPE for clustering BGCs into families, and machine learning models for discovering novel clusters. The article categorizes major BGC classes, such as non-ribosomal peptide synthetases (NRPS), polyketide synthases (PKS), and ribosomally synthesized peptides (RiPPs), discussing their diverse products and critical ecological roles in microbial competition, symbiosis, and nutrient acquisition. A significant focus is placed on overcoming the challenge of activating silent or cryptic BGCs, which are not expressed under standard lab conditions. Strategies discussed include heterologous expression in engineered host systems (chassis strains), promoter engineering, and manipulation of regulatory factors. The importance of experimental validation is stressed, with detailed workflows combining genomic data with advanced analytical techniques like mass spectrometry-based molecular networking to connect predicted BGCs to their chemical products. The role of curated databases, particularly the MIBiG repository, as a reference standard is also highlighted. The text serves as a technical guide for researchers, outlining the integrated computational and experimental approaches essential for advancing natural product discovery pipelines. Source: https://www.biosynthchem.com/posts/biosynthetic-gene-cluster-identification-from-foundational-concepts-to-advanced-applications-in-drug-discovery